Table 2.
Clinical and urodynamic findings – neurogenic detrusor overactivity receiving BoNT/A
| First author | Study design | Patients (N) neurogenic disorder | BoNT/A brand dose | Incontinence reduction (%) | MCC (ml) (before–after) | MDP (cm/H2O) (before–after) | RV (ml) |
|---|---|---|---|---|---|---|---|
| Schurch (2000)17 | Prospective Open labeled |
SCI (19) | Botox® 200 U 300 U |
89% overall |
215 → 416 | 66 → 35 | 262 → 490 |
| Reitz (2004)37 | Retrospective | 231 total SCI (67) Spina bifida 22), MS (11) |
Botox® 300 U |
73% overall |
272 → 352 | 61 → 44 At 4 months |
– |
| Schurch (2005)38 | Prospective Randomized placebo controlled Double-blind multi-center |
59 total SCI (53) MS (6) |
Botox® 200 U 300 U |
50% 300 U 50% 6 weeks |
200 U 260 → 448 300 U 293 → 462 6 weeks |
200 U 77 → 40 300 U 92 → 45 6 weeks |
200 U 169 → 234 300 U 254 → 268 |
| Grosse (2005)39 | Prospective Open labeled |
66 total SCI (54) MS (4) Other (3) |
Botox® 300 U Dysport® 750 U |
73% overall | Overall 300 → 400 |
– | – |
| Ehren (2007)41 | Prospective Randomized placebo controlled Double blind |
31 total SCI (20) MS (6) Other (4) |
Dysport® 500 U |
– | 500 U 260 → 460 at 6 weeks |
500 U 68 → 18 at 6 weeks |
– |
| Kalsi (2007)42 | Prospective Open labeled |
MS (45) | Botox® 300 U |
– | 236 → 603 At 4 weeks |
51 → 27 | >100 (98%-IC) |
| Del Popolo (2008)43 | Retrospective | SCI (199) | Dysport® 500 U 750 U 1000 U |
– | Dysport® – all doses 226 → 407 |
– | Dysport® All doses 201 → 300 |
| Giannantoni (2009)44 | Prospective Open labeled |
SCI (17) | Botox® 300 U |
88% – full | 243 → 390 At 4 months |
97.6 → 32.4 At 4 months |
– |
| Deffontaines-Rufin (2011)45 | Prospective Open labeled |
MS (71) | Botox® 300 U | 46% – full 31% – partial 23% – none |
300 U 240 → 328 at 3 months |
300 U 61 → 36 at 3 months |
NA |
| Cruz (2011)18 | Prospective Randomized Placebo-controlled Double-blind multi-center |
275 total SCI (121) MS (154) |
Placebo Botox® 200 U 300 U |
Placebo 13% 200 U – 22% 300 U – 19% |
Placebo-249 → 256 200 U 247 → 404 300 U 247 → 404 |
Placebo- 41 → 48 200 U 52 → 23 300 U 42 → 15 |
Placebo- 57 → 60 200 U 79 → 167 300 U 64 → 248 |
| Kuo (2011)40 | Prospective Open labeled |
24 total SCI (12) CVA (12) |
Botox® 200 U |
SCI 33% – full 58% – partial CVA 83% – full 42% – partial |
SCI 176–374 At 4 weeks CVA 198 → 343 At 4 weeks |
SCI 39 → 21 At 4 weeks CVA 27 → 21 At 4 weeks |
SCI 55 → 242 At 4 weeks CVA 42 → 165 At 4 weeks |
Abbreviations: MCC, mean cystometric capacity; MDP, mean detrusor pressure; RV, residual volume.